Highest-materiality recent filing
Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M
Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.
Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M
Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).
Emmaus Life Sciences licenses Endari to NeoImmuneTech for US/Canada with upfront and royalties
Emmaus grants NeoImmuneTech (NIT) exclusive rights to market Endari for sickle cell disease in US and Canada; upfront payment plus royalty on NIT sales.
Emmaus Life Sciences exchanges $3M note for $600K note and 6.33M shares (9% dilution)
Exchanged $3M convertible note (10% interest, conversion $0.13) for $600K new note (10%, conversion $0.01 adjustable) and 6,332,692 shares valued at ~$0.38 each.
Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition
Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.
Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M
Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.
Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share
Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.
Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY
Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.
Revenue falls 55% to $7.9M, net loss $6.5M; auditor Baker Tilly declines reappointment
Net revenue for H1 2024 was $7.9M, down 55% from $17.5M in H1 2023, due to inventory shortages.
Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M
Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.
On November 4, 2024, Seah Lim, M.D., Ph.D., resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) for personal reasons and expressed his best wishes to the company.
the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.
On September 30, 2024, George Sekulich resigned as a member of the Board of Directors
in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024
On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.
Max materiality 0.80 · Median 0.53 · Most common event earnings